Cambridge Advisors Inc. Gilead Sciences, Inc. Transaction History

Cambridge Advisors Inc.

$446 Million
Q3 2024

A detailed history of Cambridge Advisors Inc. transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Cambridge Advisors Inc. holds 2,650 shares of GILD stock, worth $233,968. This represents 0.05% of its overall portfolio holdings.

Number of Shares

2,650

Holding current value

$233,968

% of portfolio

0.05%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 23, 2024	BUY	$66.59 - $83.99 $176,463 - $222,573	2,650 New	2,650 $222,000
Q4 2023 Jan 16, 2024	SELL	$73.27 - $83.09 $32,238 - $36,559	-440 Reduced 14.24%	2,650 $214,000
Q4 2022 Jan 23, 2023	SELL	$62.32 - $89.47 $461,168 - $662,078	-7,400 Reduced 70.54%	3,090 $0
Q3 2022 Oct 17, 2022	BUY	$59.54 - $68.01 $5,954 - $6,801	100 Added 0.96%	10,490 $647,000
Q2 2022 Jul 18, 2022	SELL	$57.72 - $65.01 $11,544 - $13,002	-200 Reduced 1.89%	10,390 $642,000
Q1 2022 May 05, 2022	SELL	$57.92 - $72.58 $32,435 - $40,644	-560 Reduced 5.02%	10,590 $630,000
Q4 2021 Jan 14, 2022	SELL	$64.88 - $73.64 $12,976 - $14,728	-200 Reduced 1.76%	11,150 $810,000
Q2 2021 Jul 21, 2021	SELL	$63.47 - $69.35 $20,310 - $22,192	-320 Reduced 2.74%	11,350 $782,000
Q1 2021 Apr 22, 2021	BUY	$60.0 - $68.46 $150,000 - $171,149	2,500 Added 27.26%	11,670 $754,000
Q4 2020 Jan 25, 2021	SELL	$56.65 - $64.55 $12,349 - $14,071	-218 Reduced 2.32%	9,170 $534,000
Q3 2020 Oct 15, 2020	SELL	$62.1 - $78.08 $9,936 - $12,492	-160 Reduced 1.68%	9,388 $593,000
Q2 2020 Jul 17, 2020	BUY	$72.34 - $84.0 $56,063 - $65,100	775 Added 8.83%	9,548 $735,000
Q1 2020 Apr 21, 2020	BUY	$62.63 - $80.22 $85,114 - $109,018	1,359 Added 18.33%	8,773 $656,000
Q4 2019 Jan 28, 2020	SELL	$61.62 - $67.78 $3,081 - $3,389	-50 Reduced 0.67%	7,414 $482,000
Q3 2019 Oct 25, 2019	SELL	$62.51 - $69.0 $18,753 - $20,700	-300 Reduced 3.86%	7,464 $473,000
Q2 2019 Jul 26, 2019	SELL	$61.87 - $69.38 $46,402 - $52,035	-750 Reduced 8.81%	7,764 $525,000
Q1 2019 Apr 16, 2019	SELL	$62.53 - $70.05 $3,126 - $3,502	-50 Reduced 0.58%	8,514 $553,000
Q4 2018 Jan 29, 2019	SELL	$60.54 - $79.0 $63,567 - $82,950	-1,050 Reduced 10.92%	8,564 $536,000
Q3 2018 Oct 24, 2018	SELL	$71.28 - $78.92 $21,384 - $23,676	-300 Reduced 3.03%	9,614 $742,000
Q2 2018 Jul 30, 2018	SELL	$64.88 - $75.68 $9,732 - $11,352	-150 Reduced 1.49%	9,914 $702,000
Q1 2018 Apr 18, 2018	BUY	$72.84 - $88.8 $233,088 - $284,160	3,200 Added 46.62%	10,064 $759,000
Q4 2017 Jan 26, 2018	SELL	$71.15 - $83.52 $2,134 - $2,505	-30 Reduced 0.44%	6,864 $492,000
Q3 2017 Oct 27, 2017	BUY	$72.11 - $85.47 $497,126 - $589,230	6,894	6,894 $559,000

Others Institutions Holding GILD

# of Institutions

1,895

Shares Held

1.02B

Call Options Held

12M

Put Options Held

9.02M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $111B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cambridge Advisors Inc., based on Form 13F filings with the SEC.

News

Stay updated on Cambridge Advisors Inc. with notifications on news.

Account

Cambridge Advisors Inc. Gilead Sciences, Inc. Transaction History